Abstract：
BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 who were surgically treated to evaluate the proposed classifications: number, rate, nodal zone of metastatic lymph nodes. We evaluated N2 disease classification based on mediastinal lymph nodes alone in 136 pN2 cases. RESULTS:The number (1-2, 3-5, and 6 ≤) or rate (15%≥, 15%< to 40%>, and 40%≤) classification based on all metastatic lymph nodes was validated by the log-rank test and Cox proportional hazards model. After reclassification by number or rate of metastatic mediastinal lymph nodes alone, a significant difference was maintained among all groups except between the 3-5 and 6 ≤ groups. The 5-year survival rates of the 1-2, 3-5, and 6 ≤ groups were 63.4%, 32.4%, and 18.2%, respectively (1-2 vs. 3-5, P = .015; 3-5 vs. 6 ≤, P = .134). With rate classification, the 5-year survival rates of the 15%≥, 15%-40% (15%< to 40%>), and 40%≤ groups were 56.0%, 27.3%, and 5.04%, respectively (15%≥ vs. 15%-40%, P = .011; 15-40% vs. 40%≤, P = .011). The Spearman's rank correlation coefficient showed a highly significant correlation of metastatic status between mediastinal lymph nodes and all lymph nodes (both P < .001). CONCLUSION:Classification by number and rate of mediastinal lymph nodes alone enabled subdivision of N2 NSCLC cases. Metastatic status of mediastinal lymph nodes reflects that of all lymph nodes and is prognostic indicators.
journal_name
Clin Lung Cancerjournal_title
Clinical lung cancerauthors
Ito M,Yamashita Y,Tsutani Y,Misumi K,Harada H,Miyata Y,Okada Mdoi
10.1016/j.cllc.2013.04.012subject
Has Abstractpub_date
2013-11-01 00:00:00pages
651-7issue
6eissn
1525-7304issn
1938-0690pii
S1525-7304(13)00080-6journal_volume
14pub_type
杂志文章abstract：BACKGROUND:Central nervous system (CNS) progression is a common manifestation of acquired resistance to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). However, an optimal tailored treatment approach has not been established in patients with CNS failure during crizotinib tr...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.06.013
更新日期：2019-11-01 00:00:00
abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.3816/CLC.2009.n.027
更新日期：2009-05-01 00:00:00
abstract：:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2011.06.002
更新日期：2011-09-01 00:00:00
abstract：BACKGROUND:In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this hypothesis, we analyzed TP53 mutations and downregulation of p14(arf), a negative regulator of p53 activated by on...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.08.003
更新日期：2014-03-01 00:00:00
abstract：:Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib treatment in large, randomized monotherapy trials. In preclinical studies, gefitinib has shown additive and even supra-additive antitumo...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2003.s.011
更新日期：2003-09-01 00:00:00
abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.09.003
更新日期：2014-03-01 00:00:00
abstract：INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affe...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.013
更新日期：2018-01-01 00:00:00
abstract：:Traditionally, non-small-cell lung cancer (NSCLC) is not thought of as an immunosensitive malignancy. However, recent clinical results with GVAX, a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced autologous tumor vaccine, may suggest otherwise. This review summarizes immune-induced activity c...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2003.n.027
更新日期：2003-11-01 00:00:00
abstract：INTRODUCTION:The lung is a heterogeneous organ with relative overperfusion of the lung bases. We determined whether a lower lobe primary tumor location was associated with poor outcomes in the setting of stage I non-small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND ME...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.09.001
更新日期：2017-03-01 00:00:00
abstract：:Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2010.n.019
更新日期：2010-05-01 00:00:00
abstract：INTRODUCTION:We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identify the prevalence of clinically actionable EGFR mutations, to det...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.11.018
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.10.003
更新日期：2015-03-01 00:00:00
abstract：INTRODUCTION:To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation. MATERIALS AND METH...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2012.05.005
更新日期：2013-03-01 00:00:00
abstract：:The success of the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab in numerous tumor types including non-small-cell lung cancer (NSCLC) has spurred the development of additional novel antiangiogenic agents with distinct mechanisms of action. These include the small-molecule receptor tyrosine kinase...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2006.n.010
更新日期：2006-03-01 00:00:00
abstract：INTRODUCTION:In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-relat...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.cllc.2017.06.002
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS:Seventy-two patients with poor PS and advanced NSCLC were enrolled onto this study of gefitinib 250 ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.3816/CLC.2005.n.028
更新日期：2005-09-01 00:00:00
abstract：INTRODUCTION:Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS:The Surveillance, Epidemiology an...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.03.003
更新日期：2017-09-01 00:00:00
abstract：INTRODUCTION:Lung cancer is the leading cause of cancer-related death. Many patients with lung cancer are in its advanced stages at the time of diagnosis. The 5-year survival rate for lung cancer is 10% to 20%, and the prognosis for patients with lung cancer is still poor. The crosslinked N-terminal telopeptide of type...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2012.03.012
更新日期：2013-01-01 00:00:00
abstract：:Multiple studies have confirmed the value of radiation therapy in limited-stage small-cell lung cancer. The appropriate dose of radiation and the optimal fractionation scheme, however, remain controversial. This article will examine the history of radiation therapy in the management of small-cell lung cancer. It will ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2003.n.013
更新日期：2003-05-01 00:00:00
abstract：BACKGROUND:Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. METHODS:Extrusion-precipitation method and DNA methy...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.09.005
更新日期：2016-05-01 00:00:00
abstract：:The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy o...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2005.s.011
更新日期：2005-10-01 00:00:00
abstract：INTRODUCTION:We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma. MATERIALS AND METHODS:We used the Surveillance Epidemiology and End Results database to s...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.08.008
更新日期：2017-01-01 00:00:00
abstract：BACKGROUND:Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. PATIENTS AND ME...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.01.006
更新日期：2018-07-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to assess the applicability of an annual low-dose computed tomography (CT) screening program for lung cancer in a single institution in Israel, which has a relatively lower prevalence of lung cancer compared with other Western countries, and to examine stage distribution of dete...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2006.n.004
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.007
更新日期：2014-05-01 00:00:00
abstract：INTRODUCTION:Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with p...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.02.017
更新日期：2020-05-01 00:00:00
abstract：:Combined-modality therapy with chemotherapy and radiation appears to be the most efficacious therapeutic modality for patients with locally advanced non-small-cell lung cancer. Most of the trials exploring this approach have utilized older agents such as cisplatin, vinblastine, and etoposide. Recent data suggest that ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2002.s.003
更新日期：2002-03-01 00:00:00
abstract：INTRODUCTION:We set out to investigate whether volumetric tumor measurements allow for a prediction of treatment response, as measured by patient survival, in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS:Patients with nonresectable NSCLC (stage III or IV, n = 100) who were repeatedl...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.11.001
更新日期：2014-03-01 00:00:00
abstract：:Lung cancer remains the number one cause of cancer-based mortality in men and women. The importance of proper lung cancer care outside of major academic centers cannot be overemphasized because the vast majority of lung cancer care occurs in community hospital settings. We have had the opportunity to develop a highly ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2009.n.032
更新日期：2009-07-01 00:00:00
abstract：BACKGROUND:Programmed cell death 1 (PD-1) inhibitors have become a standard treatment, albeit not completely effective, for patients with advanced non-small-cell lung cancer (NSCLC). Previous studies of advanced melanoma have revealed that the tumor burden predicted the response to PD-1 inhibitors, although this relati...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2020.02.012
更新日期：2020-09-01 00:00:00
